Case report

Evolution and resolution of brain involvement associated with SARS-CoV2 infection: A close Clinical – Paraclinical follow up study of a case

Hale Afshar (MD)\textsuperscript{a}, Zeynab Yassin (MD)\textsuperscript{b}, Saeed Kalantari (MD)\textsuperscript{b}, Oldooz Aloosh (MD)\textsuperscript{a}, Tayebeh Lotfi (MD)\textsuperscript{c}, Mehdi Moghaddasi (MD)\textsuperscript{c}, Alireza Sadeghipour (MD)\textsuperscript{d}, Maziar Emamikhah (MD)\textsuperscript{e,⁎}

\textsuperscript{a}Department of Internal Medicine, School of Medicine, Hazrat- e Rasool Akram General Hospital, Iran University of Medical Sciences (IUMS), Tehran, Iran
\textsuperscript{b}Antimicrobial Resistance Research Center, Iran University of Medical Sciences (IUMS), Tehran, Iran
\textsuperscript{c}Department of neurology, School of Medicine, Hazrat Rasool-e Akram General Hospital, Iran University of Medical Sciences (IUMS), Tehran, Iran
\textsuperscript{d}Department of pathology, Oncopathology research center, Iran University of Medical Sciences (IUMS), Tehran, Iran

\textsuperscript{⁎}Corresponding author: Maziar Emamikhah, MD, Assistant professor of Neurology, Division of Neurology – Hazrat- e Rasool Akram General Hospital, Iran University of Medical Sciences (IUMS), Niyayesh St, Sattarkhan Ave, Tehran, Iran, Postal code: 1445613131, Phone: +98 21 66 52 5331, Fax: +98 21 66 52 5331. E-mail address: maziar.emamikhah@yahoo.com (M. Emamikhah).

ARTICLE INFO

Keywords:
COVID-19
SARS-CoV-2
encephalitis
post-infectious
natural history
immunotherapy

ABSTRACT

The new severe acute respiratory syndrome- coronavirus 2 is reported to affect the nervous system. Among the reports of the various neurological manifestations, there are a few documented specific processes to explain the neurological signs. We report a para-infectious encephalitis patient with clinical, laboratory, and imaging findings during evolution and convalescence phase of coronavirus infection. This comprehensive overview can illuminate the natural history of similar cases. As the two previously reported cases of encephalitis associated with this virus were not widely discussed regarding the treatment, we share our successful approach and add some recommendations about this new and scarce entity.

1. Introduction

As the new emerging coronavirus, severe acute respiratory syndrome- coronavirus 2 (SARS-CoV 2), spreads all over the world, new features of this coronavirus disease 2019 (COVID-19) is being reported. It is reported that there might be some mechanisms by which the disease can affect the central nervous system (CNS) (Li et al. 2020). Despite various neurological signs and symptoms, which have been reported (Mao et al. 2020), there are only a few reported cases with documented specific neurological processes to explain the CNS signs (Liu et al. 2020). To our knowledge, no cases of post infectious encephalitis (PIE) and its close follow up have been reported. Herein we report a case with clinical (including respiratory and neurological), laboratory, chest Computed Tomography and Brain Magnetic Resonance Imaging (B-MRI) findings during evolution and convalescence phase which can illuminate the natural history of similar cases.

2. Case report

A 39-year-old female presented to emergency department (ED) with fever, myalgias, anorexia, drowsiness and dry cough. Fever and myalgias had been present for nine days; she did not experience any improvement with rest and anti-inflammatory drug (NSAIDS). She had prolonged exposure to a covid-19 patient for prior 2 weeks. Past medical history was otherwise insignificant.

After presentation to ED (day 10), she demonstrated a decline in consciousness along with respiratory distress, ultimately needed endotracheal intubation. Chest CT showed multiple peripheral patchy ground-glass opacities with typical covid-19 distribution (day 10); these opacities later formed bilateral peripheral consolidation (day 22) (figure 1). She was transferred to intensive care unit (ICU) and treated with broad-spectrum IV antibiotics (meropenem 1g tid, levofloxacin 750 mg daily, linezolide 600 bid), hydroxychloroquine 400 mg bid for the first day, then 200 mg bid, atazanavir 400 mg daily and intravenous immunoglobulin (IVlg) 25 g/day for 3 days. RT-polymerase chain reaction (PCR) of a nasopharyngeal swab was negative for SARS-CoV 2 yet she was admitted with a diagnosis of Covid-19, based on clinical history and chest CT scan findings.

The patient experienced an episode of self-limited generalized tonic-clonic seizure (GTCS) on the following day (day 11) treated with intravenous (IV) levetiracetam 500 mg bid. She experienced another episode of GTCS on the same day, managed with increment in...
levetiracetam dosage (500 mg tid). After improvement of respiratory function, she was extubated (day 15). Despite improvement in inflammatory and metabolic tests, she had a fluctuating level of consciousness. During investigation for decreased level of consciousness, B-MRI revealed T2- fluid attenuated inversion recovery (FLAIR) high signal intensities in bilateral pons (C1 & H1) and thalami (D1 & I1) and with low signal in T1 sequences (J1-M1). Corresponding images in second and third series show considerable resolution of signal intense lesions. There was neither gadolinium enhancement nor diffusion restriction in post-contrast T1 and diffusion weighted imagings (not shown here).

serologic markers including SS-A/SS-B and Anti-phospholipid antibodies were unremarkable. There was a borderline positive anti-nuclear antibody (ANA=2.7, positive>1.2) result. Other laboratory tests and their changes during disease course are listed in table 1. These results led to the diagnosis of para- infectious encephalitis associated with COVID-19 and treatment with IVIg continued to a total dosage of 3g/kg of body weight (250g total) which resulted in considerable improvement in consciousness, but discontinued because of headaches (day 28). She complained of diplopia and was drowsy, even though the orientation seemed fully recovered (day 28). At this point, we continued the treatment with high dose methylprednisolone (500mg/day) IV for 6 days, after which the diplopia resolved and she regained complete consciousness. Subsequent B-MRIs (figure 2) showed marked resolution

![Figure 1. Axial chest CT scans of the patient at days 10 (upper row), 22 (middle row) and 28 (bottom row) after onset of symptoms.](image1)

![Figure 2. Three sets of axial (A-M except E) and coronal (E) brain MRIs obtained at days 11 (planes A1-M1), 22 (planes A2-M2) and 33 (planes A3-M3) after symptoms onset, show the evolution of brain lesions over time. There are T2-FLAIR high signal lesions in bilateral pons (A1, B1, E1, F1 & G1), medial temporal lobes (C1 & H1) and thalami (D1 & I1) and with low signal in T1 sequences (J1-M1). Corresponding images in second and third series show considerable resolution of signal intense lesions. There was neither gadolinium enhancement nor diffusion restriction in post-contrast T1 and diffusion weighted imagings (not shown here).](image2)
Table 1
The sequence of clinical, laboratory and imaging findings during the natural history of our patient’s disease.

<table>
<thead>
<tr>
<th>Days from symptoms onset</th>
<th>Day 1</th>
<th>Day 10</th>
<th>Day 11</th>
<th>Day 22</th>
<th>Day 28</th>
<th>Day 33</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical symptoms and treatments</td>
<td>Fever, Myalgia</td>
<td>First admission day Fever, Dry cough, Myalgia, Anorexia, Drowsiness</td>
<td>Starting antibiotics, hydroxychloroquine, azithromycin and IVIg (75 g in the next three days)</td>
<td>Second admission day Fever, Myalgia (?), Anorexia (?), Respiratory distress, Coma, GCS Intubation (for four days)</td>
<td>13th admission day Myalgia (?), Anorexia (?), No respiratory distress, Lethargy Reinstitution of IVIg (175 g in the next seven days; total = 250 g)</td>
<td>19th admission day Drowsiness, diplopia, headache (improved with IVIg discontinuation) IV methylprednisolone started (total dose of 3 g in the next six days)</td>
</tr>
<tr>
<td>Laboratory findings (in blood unless specified)</td>
<td>CBC (WBC=20000, Neut=15000, Lym=800, Plt=168000, CPK=540, Cr=1.6, CRP=48, ESR=31, LDH=1744, O2Sat=76%, Pro-BNP=1458, PCT=200, Tn=296, VBG (pH=7.3, pCO2=79, HCO3=18.9))</td>
<td>CBC (WBC=14600, Neut=12200, Lym=1460, Plt=180000, CPK=N/A, Cr=1.6, CRP=N/A, ESR=N/A, LDH=918, O2Sat=81%, Pro-BNP=N/A, PCT=14.96, VBG (pH=7.34, pCO2=32, HCO3=18))</td>
<td>CBC (WBC=14600, Neut=12200, Lym=1380, Plt=199000, CPK=N/A, Cr=0.8, CRP&lt;6, ESR=89, LDH=994, O2Sat=92%, Pro-BNP=N/A, PCT=14.96, VBG (pH=7.34, pCO2=32, HCO3=18))</td>
<td>CBC (WBC=4600, Neut=2990, Lym=1380, Plt=199000, CPK=N/A, Cr=0.8, CRP&lt;6, ESR=89, LDH=918, O2Sat=81%, Pro-BNP=N/A, PCT=14.96, VBG (pH=7.34, pCO2=32, HCO3=18))</td>
<td>CBC (WBC=4100, Neut=2660, Lym=1230, Plt=241000, CPK=N/A, Cr=0.8, CRP&lt;6, ESR=33, LDH=466, O2Sat=88%, Pro-BNP=N/A, PCT=0.11, Tn=N/A, VBG (pH=7.39, pCO2=64, HCO3=28))</td>
<td>CBC (WBC=15800, Neut=10400, Lym=4700, Plt=349000, CPK=N/A, Cr=0.7, CRP&lt;6, ESR=N/A, LDH=584, O2Sat=96%, Pro-BNP=N/A, PCT=N/A, Tn=N/A, VBG (pH=N/A, pCO2=N/A, HCO3=N/A))</td>
</tr>
<tr>
<td>Chest CT findings</td>
<td>- Multiple peripheral patchy ground-glass opacities</td>
<td>- T2 high signal abnormalities in bilateral thalami, Pons and medial temporal lobes</td>
<td>- Obvious peripheral consolidations in both lungs</td>
<td>- T2 high signal abnormalities in bilateral Pons</td>
<td>- Marked resolution of consolidations, hazy opacities</td>
<td>- Residual T2 signal abnormalities in lower pons</td>
</tr>
<tr>
<td>Brain MRI findings</td>
<td>-</td>
<td>-</td>
<td>- T2 high signal abnormalities in bilateral thalami, Pons and medial temporal lobes</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

CBC: complete blood count; CPK: creatin phosphokinase; Cr: creatinine; CRP: C-reactive protein (mg/L, negative < 6); CT: computed tomography; ESR: erythrocyte sedimentation rate (mm/hr); GCS: generalized tonic clonic seizure; HCO3: bicarbonate (meq/L); IVIg: intravenous immunoglobulin; LDH: lactate dehydrogenase; Lym: lymphocytes (per mm³); MRI: magnetic resonance imaging; N/A: not available; Neut: neutrophils (per mm³); O2Sat: oxygen saturation; pCO2: partial pressure of carbon dioxide (mmHg); pH: power of hydrogen; Plt: platelets (per mm³); Pro-BNP: pro-B-type natriuretic peptide (pg/ml, abnormal > 125); PCT: Procalcitonin (ng/ml, normal < 0.5); Tn: troponin- n (ng/ml, normal < 19); VBG: venous blood gas; WBC: white blood cells (per mm³); ?: unknown because of decreased consciousness
of medial temporal and thalami involvements as well as partial improvement in pontine lesions after reinstitution of IVIg (day 22) and administration of methylprednisolone (day 33). Results of SARS-CoV 2 serology tests taken during admission became available after discharge and were positive for both IgG and IgM.

3. Discussion

Brain involvement during COVID-19 pandemic has been reported in various forms, but the prevalence and proportion of each type of involvement is unknown (Mao et al. 2020, Liu et al. 2020). Stroke and encephalitis are specific CNS disorders reported in COVID-19 but there are many reports of neurological findings without obvious pathophysiological explanations. The most common reported neurological manifestations have been headache, dizziness, encephalopathy and delirium. Some of these patients have been undergone a neurological workup, yet despite reports of CNS symptoms in up to 40% of these patients, there are only few cases where distinct etiology has been discovered (Liu et al. 2020). Among these there is only one established cases of encephalitis with evidence of virus in CNS (Moriguchi et al. 2020) and another case with acute necrotizing encephalitis (ANE) but without evidence for direct viral invasion (Poyiadji et al. 2020). The distribution of cerebral lesions in MRI for our patient was similar to both aforementioned cases but with more extensive and symmetrical involvement of thalami and medial temporal lobes. The involvement of pons has not been present in previous reported cases. Contrary to the ANE case, in our patient there was no evidence for hemorrhage or necrosis in serial B-MRIs. A recent paper has described a number of B-MRI changes in COVID-19 patients, but none of them have been the same as those in our patient (Kandemirli et al. 2020). Although in ANE the authors mentioned treatment with IVIg, but exact dosage, protocol and response to treatment has not been described. Our patient before diagnosis of neurologic involvement had received IVIg (25 g/day for three days) as a part of treatment for COVID-19 severe pulmonary involvement; and after the CNS lesions were established, it was reinstituted and due to very good clinical and radiological response, we decided to continue IVIg therapy until complete recovery, unless there is a complication. After administration of a total 250 g (3 g/kg) IVIg, it was stopped due to occurrence of headaches that seemed related to drug infusion. After discontinuation of IVIg, the headaches resolved completely and due to presence of diplopia and drowsiness treatment was then continued with methylprednisolone (500 mg/day for six days), which led to complete resolution of neurological symptoms. Upon discharge from the hospital, the patient was completely asymptomatic. We consider this type of brain involvement, a para-infectious autoimmune encephalitis, as we believe was the case for ANE patient, and recommend prompt immunotherapy upon diagnosis of similar cases. The use of IVIg in severe COVID-19 patients may prevent or ameliorate CNS involvement, as seemed to happen for our patient compared to ANE case.

4. Conclusion

Neurological involvement in COVID-19 is increasingly reported and the investigations regarding etiology, natural history and appropriate treatment are essential. As for our patient, neurological symptoms not correlated with respiratory and metabolic conditions should be an alarm for the possibility of CNS involvement. Similar to many other viral agents, SARS-CoV 2 seems capable of causing encephalitis. The nature of etiology regarding encephalitis remains the matter of debate as both direct invasion and para-infectious mechanisms seem possible. We recommend prompt assessment of CSF for overt signs of viral infection (marked cellular reaction, increased protein and positive PCR test) and considering immunotherapy with IVIg in cases compatible with para-infectious origin. The usefulness of prophylactic IVIg in severe COVID-19 and the role of serology in CSF for diagnosing neuroinvasion, remain interesting discussions that we are unable to comment about at this moment.

Disclosures

Funding sources
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Compliance with ethical standards
This study was approved by the ethics committee of Iran University of Medical Sciences, Tehran, Iran and also have been conducted in accordance with the ethical standards of Declaration of Helsinki.

Informed consent was obtained from the patient for publication of this report.

CRediT authorship contribution statement

Hale Afshar: Conceptualization, Investigation, Methodology, Supervision, Writing - review & editing. Zeynab Yassin: Investigation, Methodology, Writing - review & editing. Saeed Kalantari: Investigation, Resources, Writing - review & editing. Olodoo Aaloosh: Resources, Writing - review & editing. Tayebeh Tofte: Investigation, Writing - original draft. Mehdi Moghadassi: Conceptualization, Investigation, Supervision, Writing - review & editing. Alireza Sadeghipour: Investigation, Resources. Maziar Emamikhal: Conceptualization, Data curation, Investigation, Methodology, Project administration, Resources, Software, Supervision, Writing - original draft, Writing - review & editing.

Declaration of Competing Interest

None.

Acknowledgement

None.

References


4